CLCN1 and myopathy: Thus, in spite of the evident attempt of the muscle to counteract some of the statin-induced damage, it is not able to counteract the reduction of ClC-1 protein and consequent hyperexcitability of sarcolemma, as well as the energy production deficit that appears to be one of the most important troubles associated with statin-related risk of myopathy in humans.